Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Stock Position Reduced by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. decreased its position in Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) by 40.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 99,610 shares of the biotechnology company’s stock after selling 68,461 shares during the quarter. Harbor Capital Advisors Inc. owned 0.06% of Ironwood Pharmaceuticals worth $441,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in the company. Virtu Financial LLC acquired a new position in Ironwood Pharmaceuticals in the third quarter worth $78,000. Vestcor Inc lifted its position in shares of Ironwood Pharmaceuticals by 37.8% in the 3rd quarter. Vestcor Inc now owns 159,466 shares of the biotechnology company’s stock worth $657,000 after buying an additional 43,703 shares during the last quarter. Jane Street Group LLC boosted its holdings in shares of Ironwood Pharmaceuticals by 102.7% in the 3rd quarter. Jane Street Group LLC now owns 323,638 shares of the biotechnology company’s stock valued at $1,333,000 after buying an additional 164,006 shares during the period. Wolverine Trading LLC acquired a new position in shares of Ironwood Pharmaceuticals in the 3rd quarter valued at about $51,000. Finally, Weiss Asset Management LP bought a new stake in shares of Ironwood Pharmaceuticals during the 3rd quarter valued at about $893,000.

Wall Street Analysts Forecast Growth

Separately, StockNews.com cut shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, November 12th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $10.40.

Ironwood Pharmaceuticals Stock Down 3.2 %

IRWD stock opened at $3.65 on Wednesday. The firm’s 50-day simple moving average is $4.03 and its 200 day simple moving average is $4.69. The stock has a market cap of $584.10 million, a PE ratio of -121.67 and a beta of 0.34. Ironwood Pharmaceuticals, Inc. has a fifty-two week low of $3.06 and a fifty-two week high of $15.70.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.02 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). The company had revenue of $91.60 million for the quarter, compared to the consensus estimate of $91.22 million. Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. Ironwood Pharmaceuticals’s revenue for the quarter was down 19.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.12 earnings per share. Equities analysts forecast that Ironwood Pharmaceuticals, Inc. will post 0.08 EPS for the current fiscal year.

Insider Transactions at Ironwood Pharmaceuticals

In related news, CFO Sravan Kumar Emany sold 11,001 shares of Ironwood Pharmaceuticals stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $4.08, for a total transaction of $44,884.08. Following the transaction, the chief financial officer now directly owns 309,572 shares of the company’s stock, valued at $1,263,053.76. The trade was a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 12.90% of the company’s stock.

Ironwood Pharmaceuticals Profile

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.